Skip to content

Latest commit

 

History

5 Commits

Folders and files

NameName
Last commit message
Last commit date
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Repository files navigation

Long COVID Research Project

A personal research and treatment-planning knowledge base for long COVID (Post-Acute Sequelae of SARS-CoV-2 / PASC), built from 2025–2026 clinical literature, RCT results, and specialist protocols.

What this is

A structured, source-linked synthesis of the current state of long COVID science — organized around:

  1. A unified root-cause model (the "Damaged Triad" hypothesis: gut, endothelium, vagus nerve as a self-reinforcing loop)
  2. Treatment options by evidence tier (RCTs, case series, experimental)
  3. Practical protocols for specific drugs (e.g., bupropion) and lifestyle interventions
  4. Curated primary sources organized by topic

Built collaboratively with Claude (Anthropic) using research and reasoning across the 2025–2026 literature.

What this is NOT

  • ❌ Medical advice
  • ❌ A substitute for a physician
  • ❌ A peer-reviewed publication
  • ❌ Guaranteed accurate — this is a working understanding subject to update as new evidence emerges

All content is for educational/personal-planning purposes only. Consult a qualified physician before making any medical decisions.


Structure

long_covid/
├── README.md                  ← You are here
├── CLAUDE.md                  ← Instructions for AI collaboration
├── LICENSE                    ← MIT
├── .gitignore                 ← Personal notes excluded by default
├── docs/                      ← Public research content
│   ├── 01-triad-model.md      ← Root-cause hypothesis (hardware layer)
│   ├── 02-treatments.md       ← Treatment evidence tiers
│   ├── 03-bupropion-guide.md  ← Bupropion practical guide
│   ├── 04-unified-model.md    ← The Stuck Sickness Program (full unified RCA)
│   ├── 05-mast-cell-gut-protocol.md ← Food-reactive / mast-cell phenotype: anatomy, drugs (India), tests
│   └── sources.md             ← Curated references
└── personal/                  ← Personal application (gitignored)
    ├── README.md              ← Personal entry point
    ├── profile.md             ← Personal symptom profile
    └── action-plan.md         ← Personal 90-day plan

Reading order

New readers should go:

  1. docs/04-unified-model.md — The full unified RCA (start here)
  2. docs/01-triad-model.md — The hardware layer (which tissues and why)
  3. docs/02-treatments.md — What actually works and doesn't
  4. docs/03-bupropion-guide.md — Deep-dive on one high-relevance drug
  5. docs/05-mast-cell-gut-protocol.md — The gut mast-cell / vagal-afferent phenotype and its protocol
  6. docs/sources.md — Primary literature

Core hypothesis (one paragraph)

Long COVID is a self-sustaining inflammatory loop between the gut epithelium, vascular endothelium, and vagus nerve — three ACE2-receptor-rich tissues SARS-CoV-2 preferentially damages. Once damaged, each leg feeds injury to the other two, forming a positive-feedback cycle that continues long after the acute virus is cleared. Every observed long COVID phenomenon — microclots, neuroinflammation, mitochondrial dysfunction, serotonin depletion, dopamine loss, HPA flattening, POTS, autoantibodies, EBV reactivation, PEM — is downstream of this loop. Full recovery requires breaking the loop at multiple points simultaneously, which explains why single-drug trials keep failing while multi-modal protocols at LC clinics succeed.

See docs/01-triad-model.md for the full model, mapped observations, and mechanistic evidence.


Key 2025–2026 findings compiled here

Finding Source
Fluvoxamine reduces LC fatigue significantly (RCT) REVIVE trial, Annals Int Med March 2026
Dopamine terminal density loss in striatum documented 2026 Nature-published imaging study
Fibrinaloid microclots — 4 distinct subtypes identified Pretorius group, PolyBio Symposium 2026
Nicotinamide Riboside modest fatigue benefit (RCT) Lancet eClinicalMedicine 2025
Vagus nerve stimulation improves autonomic + fatigue taVNS: no benefit over sham in 4 controlled trials COVIVA, Neurol Ther 2026 (n=45) + Percin 2025, Vienna 2025, Mayo nVNS
Gut viral RNA/antigen persistence documented to ~22–30 months; nothing at 4–5 years; blood antigen does not track symptoms Peluso 2024 Sci Transl Med; Hany 2024; Mateu 2026
Metformin does NOT treat existing LC REVIVE trial 2026
Extended Paxlovid does NOT treat LC RECOVER-VITAL 2025
Antihistamine (H1+H2): small (−1.5 FAS points), transient fatigue benefit in unselected LC; food-reactive subgroup untested STIMULATE-ICP, Wall 2026, Lancet Infect Dis (n=778, open-label)
Bifidobacterium synbiotic (SIM01) ~doubles odds of improvement in fatigue, memory, concentration, GI symptoms Lau 2024, Lancet Infect Dis (RCT, n=463)
Gut mast-cell activation + persistent viral protein in ileal biopsies 15–22 months post-infection Augustin 2026, Mucosal Immunol
Stellate ganglion block — 56% improved in largest series (n=102), durable in ~1/3 of responders, 25% transient AEs; sham RCTs started 2026 Chiang 2025 Cureus; Peddireddy 2026 SR; NCT07468604

Contributing

This is a personal research project. If you're another long COVID researcher, patient, or clinician who wants to suggest additions/corrections:

  • Open an issue with the specific citation
  • Reference primary literature (RCTs, meta-analyses, mechanism papers) rather than blog posts where possible
  • Flag anything that turned out to be wrong so I can update

License

MIT — free to use, modify, redistribute with attribution. See LICENSE.

Acknowledgments

  • NIH RECOVER Initiative for the trial infrastructure
  • Patient-Led Research Collaborative for pushing the field forward
  • Berlin Cures, Yale (Arnsten group), Pretorius group, RTHM clinic for mechanism + treatment research
  • Anthropic / Claude for research assistance in compiling this synthesis

This is a living document. Last updated: 2026-08-18.

About

Long Covid Research AI Agent - Treatment & Cure

Topics

Resources

Stars

1 star

Watchers

0 watching

Forks

Releases

Packages

Contributors